Cipla is currently trading at Rs. 363.30, up by 1.35 points or 0.37% from its previous closing of Rs. 361.95 on the BSE.
The scrip opened at Rs. 364.00 and has touched a high and low of Rs. 366.00 and Rs. 361.35 respectively. So far 84,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 395.45 on 10-Sep-2012 and a 52 week low of Rs. 284.00 on 11-Nov-2011.
Last one week high and low of the scrip stood at Rs. 370.50 and Rs. 358.80 respectively. The current market cap of the company is Rs. 29,170 crore.
The promoters holding in the company stood at 36.80% while Institutions and Non-Institutions held 34.23% and 28.73% respectively.
Cipla has received a tentative approval from United States Food and Drug Administration (US FDA) for its HIV treatment tablets, which have a combination of lamivudine, nevirapine and zidovudine drugs.
The company sells the combination drug under the brand name ‘Duovir N’ outside the United States.
Cipla focuses on development of new formulations and has a wide range of pharmaceutical products. It offers prescription drugs, bulk drugs, animal products and pesticides. It also offers a wide range of food and beverages, baked foods, oral hygiene products, detergents, room fresheners and personal care products.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1911.70 |
| Dr. Reddys Labs. | 1365.90 |
| Cipla | 1465.65 |
| Zydus Lifesciences | 1161.85 |
| Lupin | 2499.00 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: